Codon Devices Signs Distribution Agreement with Open Biosystems.

Expands Access to Industry-Leading Gene Synthesis Offering

CAMBRIDGE, Mass. -- Codon Devices, Inc., the Constructive Biology Company[TM], announced today that it has entered into an agreement in which Open Biosystems will distribute Codon Devices' industry-leading gene synthesis offering in North America.

Central to its vision of Constructive Biology[TM], Codon Devices is driving wide-spread adoption of high-quality, low-cost synthetic genes. To date, the Company has maintained a minimum order threshold and thus access to its proprietary, industrial-scale BioFAB[TM] platform has been restricted to researchers with large-scale requirements. Under the terms of the agreement, Open Biosystems will sell and distribute Codon Devices' gene synthesis offering to researchers with needs that fall below Codon's minimum order threshold. The partnership will enable a wide range of new customers to utilize high-quality, low-cost gene synthesis in their research, and will greatly strengthen Codon Devices' presence within academic, government and other non-profit institutions.

"Through aggressive investments in its BioFAB[TM] platform, Codon Devices has moved quickly to industrialize synthetic biology and become a world leader in gene synthesis," said Brian Pollock, Chief Executive Officer, Open Biosystems. "We are delighted to provide our customers with a new product offering that is clearly revolutionizing how life science research is conducted."

"We are excited to work with Open Biosystems to provide our gene synthesis offering to a wider range of customers," said John P. Danner, President and Chief Executive Officer, Codon Devices. "This partnership will enable more customers to access our BioFAB[TM] platform and harness the power of Constructive Biology[TM] to accelerate their research. These scientists will drive entirely new fields of academic exploration and advance groundbreaking applications in human health, agriculture, and renewable energy."

About Codon Devices

Codon Devices, Inc., based in Cambridge, MA, is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity of its industrial, pharmaceutical and academic customers in a paradigm shift to what the Company calls Constructive Biology[TM]. The Company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and energy. Codon Devices' BioFAB[TM] platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. More information about Codon Devices is available at www.codondevices.com.